Last reviewed · How we verify
NCT03554343
Sun May Arise on SMA : Newborn Screening of Spinal Muscular Atrophy in Belgium
trial testing test for SMN1 exon 7 deletion in Spinal Muscular Atrophy in 136,339 participants. Completed in 28 February 2021.
28 February 2021
Quick facts
| Lead sponsor | Centre Hospitalier Régional de la Citadelle |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 136,339 |
| Start date | 5 March 2018 |
| Primary completion | 28 February 2021 |
| Estimated completion | 28 February 2021 |
| Sites | 1 location across Belgium |
Drugs / interventions tested
- test for SMN1 exon 7 deletion
Conditions studied
- Spinal Muscular Atrophy — all drugs for Spinal Muscular Atrophy →
Sponsor
Centre Hospitalier Régional de la Citadelle
Who can join
Under 7 Days, any sex, with Spinal Muscular Atrophy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Medico-economic study of Newborn screening of Spinal Muscular Atrophy
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Novel challenges in spinal muscular atrophy - How to screen and whom to treat?
Saffari A, Kölker S, Hoffmann GF, Weiler M, et al · · 2019 · cited 26× · PMID 30656198 · DOI 10.1002/acn3.689
Verify or expand the search:
- PubMed search for NCT03554343
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Spinal Muscular Atrophy
Currently open trials in the same condition.
- NCT07478172 — Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease · NA · recruiting
- NCT06955897 — Characterizing Perceived Physical Fatigability in Nusinersen-treated SMA · recruiting
- NCT06396325 — A Registry Based Randomized-Controlled Trial of an Upper Limb Exergaming Intervention for Children and Adolescents With · NA · recruiting
- NCT06288230 — An Open Label Study of Gene Therapy Product (Vesemnogene Lantuparvovec) in Spinal Muscular Atrophy · Phase 1, PHASE2 · recruiting
- NCT06321965 — Characterization of New Phenotypes of Patients With Spinal Muscular Atrophy Treated With SMN Restoring Therapy · NA · recruiting
Other Centre Hospitalier Régional de la Citadelle trials
Trials by the same sponsor.
- NCT05270486 — Safety and Efficacy of Electromagnetic Navigation System Assisted Percutaneous Endoscopic Lumbar Decompression · unknown
- NCT05326698 — Evoked Potential Response to Full-endoscopic Cervical Foraminotomy · completed
- NCT04086199 — Spinal Approach for Lumbar Active Discopathy · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03554343 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Régional de la Citadelle
- Last refreshed: 10 March 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03554343.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing